系統性幼年特發性關節炎市場－全球產業規模、佔有率、趨勢、機會、預測：按治療類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球幼年型慢性關節炎市場預計將從 2025 年的 19.3 億美元成長到 2031 年的 23.1 億美元，複合年成長率為 3.04%。

幼年特發性系統性關節炎 (sJIA) 是一種罕見的自體發炎性疾病，其特徵是每日發燒、出現特徵性皮疹以及涉及關節和內臟器官的廣泛發炎。市場成長主要得益於先進生物目標療法的持續研發以及診斷方案的改進，這些改進使得早期臨床干預成為可能。根據美國關節炎基金會估計，到 2024 年，全球將有約 300 萬名兒童和青少年患有幼年特發性關節炎，這表明患者群體非常龐大，對有效的治療策略，特別是像 sJIA 這樣的重症類型，有著極高的需求。

然而，由於先進生物製藥價格極為昂貴，該領域面臨許多重大障礙。沉重的經濟負擔阻礙了患者獲得藥物，加重了醫療預算的負擔，最終阻礙了市場的進一步擴張。

市場促進因素

白細胞介素-1 (IL-1) 和白細胞介素-6 (IL-6) 抑制劑的日益普及正在從根本上改變幼年特發性系統性關節炎 (sJIA) 的臨床治療。這些標靶生物製藥能夠精準抑制導致該疾病嚴重自體發炎症狀的細胞激素風暴，從而實現比傳統糖皮質激素更有效、更持久的疾病控制。這種向精準醫療的策略轉變正在顯著推動我們自主研發生物製藥的商業性成長。例如，諾華公司於2024年10月報告稱，其領先的sJIA IL-1BETA抑制劑Ilaris（卡那單抗）在2024年第三季的全球銷售額達到3.72億美元，年增12%。這一強勁的銷售業績凸顯了先進生物製藥在治療這種複雜疾病的重要性。尤其值得注意的是，據估計，到 2024 年，sJIA 將佔所有幼年特發性關節炎 (JIA) 病例的 10% 至 20%，而且對這種特殊治療方法的需求明顯高於其他疾病。

同時，隨著經濟實惠的生物相似藥的推出，市場正經歷顯著的結構性變化，經濟壁壘也逐漸消除。隨著原廠生物製藥專利的到期，生物相似藥的進入刺激了市場競爭，並透過減輕醫療系統的經濟負擔，為更多患者提供了治療機會。 2024年4月，費森尤斯卡比宣佈在美國推出托珠單抗生物相似藥Tyenne，該產品已獲得靜脈注射和皮下注射兩種給藥途徑的監管核准。對於需要長期接受IL-6受體拮抗劑治療的患者而言，該產品提供了前所未有的柔軟性和經濟性。預計生物相似藥的激增將繼續擴大市場規模，使更多先前因原廠藥高昂費用而無法獲得治療的兒童患者能夠更便捷地獲得改變人生的全身型幼年特發性關節炎（sJIA）治療。

市場挑戰

先進生物製藥的高成本是全球幼年特發性關節炎（sJIA）治療市場擴張的主要障礙。這些高昂的成本迫使醫療支付者和保險公司實施嚴格的成本控制措施，例如預先核准和階梯治療方案。因此，高昂的價格造成了臨床需求與實際市場收入之間的差距。這是因為行政障礙常常會延誤甚至剝奪患者獲得這些必要治療的機會。這種高度嚴格的財務審查環境限制了潛在患者群體，並嚴重阻礙了昂貴治療方法的推廣應用。

近期產業數據進一步量化了這項挑戰，凸顯了進入障礙的嚴重性。美國風濕病學會在2025年報告中指出，約89%的風濕症醫師經常遇到患者因保險障礙（例如預先核准）而延遲接受處方治療的情況。如此高的行政干預率直接限制了生物製藥的實際發放和報銷數量。這些經濟障礙迫使患者經歷複雜的核准流程或強迫他們先嘗試更便宜的替代療法，嚴重阻礙了市場進一步成長和產生收入潛力。

市場趨勢

Janus激酶（JAK）抑制劑作為替代治療方案的出現，正在改變幼年型慢性關節炎（sJIA）的治療模式，尤其適用於對標準生物製藥製劑治療無效的患者。這一趨勢的驅動力在於，臨床上對有效口服治療方法的需求日益成長，以應對伴隨危及生命的併發症（例如間質性肺病）的複雜病例，而傳統單株抗體的療效可能有限。 Medscape在2024年12月發表的一項基於患者數據分析的報告凸顯了臨床策略的這一重大轉變：57.1%的sJIA相關肺病患者正在使用託法替尼，而未出現該併發症的患者中僅有5.7%使用託法替尼。這些數據表明，小分子抑制劑市場有望大幅擴張，以滿足一線療法療效不佳的高風險患者亞群的需求。

同時，除IL-1和IL-6之外，針對細胞激素的新型標靶治療也不斷取得進展，尤其關注干擾素-γ (IFN-γ) 抑制劑，旨在控制巨噬細胞活化症候群 (MAS)，這是全身型幼年特發性關節炎 (sJIA) 的嚴重併發症。這項進展標誌著治療方向正轉向能夠更精準地控制過度發炎細胞激素風暴的藥物，而這種風暴通常難以被現有生物製藥控制。為了展現這種獨特作用機制日益成長的商業性潛力，Sobi公司在其2024年7月發布的2024年第二季度報告中指出，用於治療這些過度炎症性疾病的靶向干擾素-γ抑製劑抗體Gamifant的全球銷售額在該季度達到了5.22億瑞典克朗。這項銷售成長顯示治療方案正在實現策略多元化，並支持市場朝著能夠為最嚴重的全身性自體發炎性疾病帶來救命療效的新標靶方向發展。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：系統性幼年特發性關節炎的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療類型（藥物治療{抗發炎藥物（NSAIDs）、腫瘤壞死因子（TNF）抑制劑、肌肉鬆弛劑、免疫抑制劑、緩解疾病抗風濕藥、其他}、生物製藥、其他）
  • 給藥途徑（口服、注射、其他）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美系統性幼年特發性關節炎市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲系統性幼年特發性關節炎市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區系統性幼年特發性關節炎市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲系統性幼年特發性關節炎市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲系統性幼年特發性關節炎市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球系統性幼年特發性關節炎市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Sanofi SA
• Amgen Inc.
• Regeneron Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Systemic Juvenile Idiopathic Arthritis Market is projected to expand from USD 1.93 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 3.04%. Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare autoinflammatory condition marked by daily fevers, distinctive rashes, and widespread inflammation affecting both joints and internal organs. The market's growth is predominantly fueled by the ongoing development of advanced targeted biologic therapies and enhanced diagnostic protocols that facilitate earlier clinical intervention. The Arthritis Foundation estimated that in 2024, approximately 3 million children and young adults worldwide were affected by juvenile idiopathic arthritis, highlighting a significant patient population and a substantial demand for effective management strategies, especially for severe subtypes like sJIA.

However, the sector faces a significant hurdle due to the exceedingly high costs associated with advanced biologic medications. These considerable financial burdens pose barriers to patient accessibility and strain healthcare budgets, consequently impeding the broader expansion of the market.

Market Driver

The increasing adoption of interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors is fundamentally transforming the clinical management of systemic juvenile idiopathic arthritis (sJIA). These targeted biologic therapies precisely address the cytokine storms responsible for the disease's severe autoinflammatory symptoms, offering more effective, long-term disease control than traditional corticosteroids. This strategic shift towards precision medicine has significantly boosted commercial growth for proprietary biologic formulations; for instance, Novartis reported in October 2024 that global sales of Ilaris (canakinumab), a key IL-1 beta inhibitor for sJIA, reached USD 372 million in Q3 2024, a 12% year-over-year increase. This robust revenue performance underscores the critical reliance on advanced biologics to manage this complex condition, especially given that sJIA accounted for an estimated 10% to 20% of all juvenile idiopathic arthritis cases in 2024, driving disproportionate demand for these specialized treatments.

Concurrently, the market is experiencing a notable structural evolution driven by the introduction of cost-effective biosimilars, which are progressively removing financial barriers to access. As patents for original biologics expire, the entry of biosimilar alternatives fosters greater market competition and alleviates the economic strain on healthcare systems, thereby broadening patient reach. A significant development occurred in April 2024 with Fresenius Kabi's announcement of the U.S. launch of Tyenne, a tocilizumab biosimilar, which uniquely received regulatory approval for both intravenous and subcutaneous administration. This product offers unprecedented flexibility and affordability for patients requiring chronic IL-6 receptor antagonist therapy. This proliferation of biosimilars is anticipated to sustain market volume growth by making life-altering sJIA treatments more accessible to a wider pediatric population previously constrained by the prohibitive costs of originator drugs.

Market Challenge

The prohibitive costs associated with advanced biologic medications represent a primary impediment to the expansion of the Global Systemic Juvenile Idiopathic Arthritis Market. These elevated financial requirements compel healthcare payers and insurance providers to implement stringent cost-containment measures, such as prior authorization and step therapy protocols. As a result, the high price effectively disconnects clinical demand from actual market revenue, since administrative hurdles frequently delay or deny patient access to these essential treatments. This environment of financial scrutiny limits the addressable patient pool and creates a significant bottleneck in the adoption of premium therapies.

This challenge is further quantified by recent industry data underscoring the severity of access barriers. The American College of Rheumatology reported in 2025 that approximately 89% of rheumatologists regularly encountered delays in patient access to prescribed treatments due to insurance barriers like prior authorization. Such high rates of administrative interference directly restrict the volume of biologic prescriptions that are successfully filled and reimbursed. By obliging patients to navigate complex approval processes or first try cheaper alternatives, these economic barriers significantly dampen the market's potential for broader growth and revenue generation.

Market Trends

The emergence of Janus kinase (JAK) inhibitors as alternative treatment options is transforming the therapeutic landscape for systemic juvenile idiopathic arthritis (sJIA), particularly for patients who do not respond to standard biologic regimens. This trend is driven by a growing clinical need for effective oral interventions to manage complex cases involving life-threatening complications, such as interstitial lung disease, where traditional monoclonal antibodies may show limited efficacy. Highlighting this significant shift in clinical strategy, Medscape reported in December 2024 that analysis of patient data revealed 57.1% of patients with sJIA-associated lung disease had used tofacitinib, compared to only 5.7% of those without this complication. This data underscores the critical expansion of the market toward small molecule inhibitors to address high-risk patient subgroups who remain underserved by first-line therapies.

Simultaneously, the sector is witnessing advancements in novel cytokine-targeted therapies beyond IL-1 and IL-6, specifically focusing on interferon-gamma (IFN-y) inhibition to manage macrophage activation syndrome (MAS), a severe sJIA complication. This development represents a move toward agents that offer more precise control over the hyperinflammatory cytokine storms often resistant to existing biologic controls. Evidencing the growing commercial traction of this distinct mechanism, Sobi reported in its Q2 2024 Quarterly Report in July 2024 that global revenue for Gamifant, a targeted interferon-gamma blocking antibody used in these hyperinflammatory contexts, reached SEK 522 million for the quarter. This revenue growth indicates a strategic diversification in the therapeutic arsenal, validating the market's progression toward novel targets that offer life-saving outcomes for the most acute forms of systemic autoinflammation.

Key Market Players

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Sanofi S.A.
• Amgen Inc.
• Regeneron Pharmaceuticals, Inc.

Report Scope

In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type

• Drug Treatment
• Biologics
• Other

Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration

• Oral
• Injectables
• Other

Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Systemic Juvenile Idiopathic Arthritis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.

Available Customizations:

Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other)
  • 5.2.2. By Route of Administration (Oral, Injectables, Other)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Systemic Juvenile Idiopathic Arthritis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Systemic Juvenile Idiopathic Arthritis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Systemic Juvenile Idiopathic Arthritis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Pfizer Inc.
• 15.4. Johnson & Johnson
• 15.5. AbbVie Inc.
• 15.6. Bristol-Myers Squibb Company
• 15.7. Eli Lilly and Company
• 15.8. Sanofi S.A.
• 15.9. Amgen Inc.
• 15.10. Regeneron Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer